Chemomab Therapeutics (CMMB) Equity Average (2018 - 2025)

Chemomab Therapeutics (CMMB) has 8 years of Equity Average data on file, last reported at $11.8 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 21.07% year-over-year to $11.8 million; the trailing twelve-month figure through Dec 2025 stood at $11.8 million (down 21.07% YoY), and the FY2025 full-year result was $12.9 million, down 15.27% from the prior year.
• Equity Average for Q4 2025 stood at $11.8 million, up from $10.5 million in the prior quarter.
• Across five years, Equity Average topped out at $66.8 million in Q3 2021 and bottomed at $10.0 million in Q2 2025.
• The 5-year median for Equity Average is $22.5 million (2023), against an average of $31.1 million.
• The widest annual swing landed in 2021, when Equity Average soared 453.06%; it then plunged 58.5% in 2023.
• A 5-year view of Equity Average shows it stood at $63.5 million in 2021, then slumped by 36.33% to $40.4 million in 2022, then sank by 56.66% to $17.5 million in 2023, then slipped by 14.8% to $14.9 million in 2024, then dropped by 21.07% to $11.8 million in 2025.
• The last three Equity Average figures came in at $11.8 million (Q4 2025), $10.5 million (Q3 2025), and $10.0 million (Q2 2025), per Business Quant data.

Peer Comparison